Receptor activator of nuclear factor kappa-B ligand-induced osteoclastogenesis signaling pathway (RANKL-induced osteoclastogenesis pathway)

The RANKL-induced osteoclastogenesis signaling pathway describes the sequence of molecular events triggered when receptor activator of nuclear factor kappa-B ligand (RANKL, also known as TNFSF11) binds its cognate receptor RANK on precursor cells. This interaction initiates intracellular cascades involving MAPK/PI3K/Akt/NFATc1 pathways that drive the differentiation and activation of multinucleated osteoclasts, which are responsible for bone resorption. The process is tightly regulated by endogenous inhibitors such as osteoprotegerin (OPG) that act as decoy receptors preventing excessive activity. Dysregulation leads to pathological conditions characterized by abnormal bone loss or immune dysfunction. While not itself a single therapeutic target molecule but rather a critical biological process/pathway in skeletal biology and immunology, several approved therapies intervene at key nodes within this cascade—most notably monoclonal antibodies against human RANKL used in osteoporosis treatment.

Other names

RANKL-RANK signaling pathwayOsteoclast differentiation pathwayTNFSF11-mediated osteoclastogenesisTRANCE/ODF/OPGL-induced bone resorption cascade

For drugs like denosumab targeting this axis: Inhibition of the binding between RANKL and its receptor RANK, thereby blocking downstream signals required for osteoclast formation and activity, or decoy receptor mechanisms that sequester circulating RANKL.